RA
VRDN icon

Rosalind Advisors’s Viridian Therapeutics VRDN Stock Holding History

Rosalind Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.7K Buy
+263,600
New +$7.83M 0.02% 36

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rosalind Advisors's VRDN Position: Q1 2026 in Review

Rosalind Advisors reduced its Viridian Therapeutics (VRDN) stake by 44% in Q1 2026, selling an estimated $5.93M and leaving 250,401 shares worth $4.9M. The position accounts for 1.97% of the portfolio, ranked #18.

Rosalind Advisors first reported a position in VRDN in Q4 2023 and has held it in 8 quarters since. The position peaked at $14M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Rosalind Advisors held 250,401 shares of Viridian Therapeutics worth $4.9M as of Q1 2026.
  • Rosalind Advisors sold 199,599 Viridian Therapeutics shares in Q1 2026, an estimated $5.93M.
  • Viridian Therapeutics made up 1.97% of Rosalind Advisors's portfolio in Q1 2026, its #18 holding.
  • Rosalind Advisors first reported a position in Viridian Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • Rosalind Advisors's Viridian Therapeutics position peaked at $14M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.